Sera Prognostics
Providing individualized risk assessment to predict and manage premature birth, preeclampsia, and other pregnancy complications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
$100m | Series E | ||
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (31 %) | 228 % | 227 % | 14 % | (75 %) | 382 % | 438 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (68456 %) | (41784 %) | (16465 %) | (12183 %) | (42929 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (79392 %) | (42694 %) | (16487 %) | (11844 %) | (42725 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 31128 % | 13438 % | 5315 % | 4975 % | 19130 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Sera Prognostics, Inc. is a healthcare company focused on improving the lives of women and babies through individualized prenatal care. The company operates in the medical diagnostics market, specifically targeting the early prediction of preterm birth risk. Sera Prognostics serves healthcare providers and pregnant women, offering its flagship product, the PreTRM test, which uses proteomic technology to predict the likelihood of preterm birth. This test provides critical information to physicians, enabling them to take proactive measures to improve patient outcomes and reduce healthcare costs. Sera Prognostics generates revenue by selling the PreTRM test to healthcare providers and through partnerships with healthcare organizations. The company is transitioning from a clinical-stage to a commercial-stage entity, aiming to expand its market presence and impact.
Keywords: prenatal care, preterm birth, proteomic test, healthcare providers, pregnancy, diagnostics, patient outcomes, healthcare economics, clinical-stage, commercial-stage.